Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer

NCT00704730 is registered in ClinicalTrials.gov with Exelixis as lead sponsor.

NCT NCT00704730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00704730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Randomized, Double-Blinded, Phase 3 Efficacy Study of XL184 Versus Placebo in Subjects With Unresectable, Locally Advanced, or Metastatic Medullary Thyroid Cancer
Lead sponsor
Exelixis
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2008
Completion date
September 30, 2020
Enrollment
330 (actual)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

thyroid cancer